TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12195253

Group type: EXPERIMENTAL
Intervention: Cemented all-polyethylene glenoid component
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cementless metal-backed glenoid component
Number of subjects: 39
Study: 31394243

Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nonsurgical management
Number of subjects: 70
Study: 29855100

Group type: EXPERIMENTAL
Intervention: Group 1 (thin mucosal tissue)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Group 2 (medium mucosal tissue)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Group 3 (thick mucosal tissue)
Number of subjects: 55
Study: 26678611

Group type: EXPERIMENTAL
Intervention: Interactive game-based balance training including repetitive weight shifting and virtual obstacle crossing tasks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CG) received no exercise intervention and continued their normal activity
Number of subjects: 22
Study: 24814934

Group type: EXPERIMENTAL
Intervention: Positive mood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative mood
Number of subjects: 0
Study: 23327032

Group type: EXPERIMENTAL
Intervention: 5 mg hyperbaric bupivacaine 0.5%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 7.5 mg hyperbaric bupivacaine 0.5%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10 mg hyperbaric bupivacaine 0.5%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 12.5 mg hyperbaric bupivacaine 0.5%
Number of subjects: 80
Study: 20159310

Group type: EXPERIMENTAL
Intervention: MEDI-545 (0.3-30.0 mg/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17610061

Group type: EXPERIMENTAL
Intervention: Enhanced Triple P-Positive Parenting Program
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Standard Triple P-Positive Parenting Program
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Self Directed Triple P-Positive Parenting Program
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Enhanced, Standard, and Self Directed Triple P-Positive Parenting Programs
Number of subjects: 139

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 139
Study: 15609026

Group type: EXPERIMENTAL
Intervention: Water + Cur
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Water - Cur
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dry Land (DL)
Number of subjects: 6
Study: 12047494

Group type: EXPERIMENTAL
Intervention: Olanzapine monotherapy 5-20 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10442363

Group type: EXPERIMENTAL
Intervention: Adjuvant UFT (400 mg/day for 12 months)
Number of subjects: 139

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 139

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 139
Study: 8578802

Group type: EXPERIMENTAL
Intervention: Diphtheria/Tetanus/Pertussis (DTP) vaccine
Number of subjects: 190

Group type: COMPARATOR
Intervention: Diphtheria/Tetanus (DT) vaccine
Number of subjects: 190
Study: 2190540

Group type: EXPERIMENTAL
Intervention: Oral low dose cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous high dose cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral placebo treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (both doses)
Number of subjects: 0
Study: 378731

Group type: EXPERIMENTAL
Intervention: Long-acting formulation of propranolol ('Inderal' LA) given once daily
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional propranolol tablets given twice daily
Number of subjects: 29
Study: 30640148

Group type: COMPARATOR
Intervention: Cued Self-Monitoring (TRACK)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Combination of BCTs (COMBO)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Drinking Intentions Feedback (PLAN)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Drinking Performance Feedback (USE)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Adaptive Goal Support (GOAL)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessments (EMA)
Number of subjects: 149
Study: 29096631

Group type: EXPERIMENTAL
Intervention: Multivariable logistic regression model including sociodemographic, clinical and biochemical factors
Number of subjects: 1409

Group type: EXPERIMENTAL
Intervention: Simpler model including clinical factors only (no biomarkers)
Number of subjects: 1409

Group type: EXPERIMENTAL
Intervention: Increasing predicted risk of uncomplicated pregnancy and birth
Number of subjects: 1409
Study: 24652539

Group type: EXPERIMENTAL
Intervention: Twin mix (dexamethasone and lignocaine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% lignocaine with 1:200,000 epinephrine
Number of subjects: 0
Study: 23877691

Group type: EXPERIMENTAL
Intervention: GS-5885 1 mg once daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GS-5885 ≥3 mg once daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GS-5885 30 mg and 90 mg once daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GS-5885
Number of subjects: 10
Study: 20309694

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (CyP) (500 mg/m² of body surface monthly) and antioxidants (alpha-tocopherol 400 IU/day and ascorbic acid 1,000 mg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (CyP) only
Number of subjects: 13
Study: 18280789

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 180
Study: 16464962

Group type: EXPERIMENTAL
Intervention: Combined use of paracetamol and ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 12957421

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) infusion for 8 to 12 hours
Number of subjects: 940

Group type: COMPARATOR
Intervention: Control group (no infusion)
Number of subjects: 940
Study: 10830661

Group type: EXPERIMENTAL
Intervention: Reconstruction of the anterior talo-fibular ligament using a semi-tendinosis free graft
Number of subjects: 26
Study: 8891888

Group type: EXPERIMENTAL
Intervention: Isocaloric, reduced fat (< 30%) low‐cholesterol diet with placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isocaloric, reduced fat (< 30%) low‐cholesterol diet with pravastatin (40 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (10 normocholesterolemic healthy subjects)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both interventions (diet with pravastatin and diet with placebo)
Number of subjects: 20
Study: 1992396

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia
Number of subjects: 88

Group type: COMPARATOR
Intervention: Continuous epidural infusion
Number of subjects: 88
Study: 6603074

Group type: EXPERIMENTAL
Intervention: Combined exercises consisting of gymnastics and walking according to the interval principle (twice a week), sauna visits twice a week, diadynamic series of the current.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Walking group (specific details not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sauna group (specific details not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interval walking (specific details not provided)
Number of subjects: 0
Study: 31101732

Group type: EXPERIMENTAL
Intervention: Simplified adductor canal (SAC) block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Adductor canal block (ACB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SAC block
Number of subjects: 40
Study: 28816281

Group type: EXPERIMENTAL
Intervention: Intravenous flurbiprofen axetil (1 mg/kg) 1 hour before the procedure
Number of subjects: 81

Group type: COMPARATOR
Intervention: Intrarectal 5% lidocaine gel (60 mg) 5 minutes before the procedure
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Intrarectal 5% lidocaine gel (60 mg) 5 minutes before the procedure and intravenous flurbiprofen axetil (1 mg/kg) 1 hour before the procedure
Number of subjects: 81
Study: 25233242

Group type: EXPERIMENTAL
Intervention: Herbal medicine
Number of subjects: 146

Group type: COMPARATOR
Intervention: Psychotropic medications
Number of subjects: 146
Study: 23752495

Group type: EXPERIMENTAL
Intervention: NSP-enriched diet (42 g NSP, 2.5 g RS)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: RS-enriched diet (16 g NSP, 25 g RS)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Weight loss diet (30% calories, 8 MJ/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Energy-maintenance diet (27 g NSP and 5 g RS)
Number of subjects: 14
Study: 22052140

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 19361582

Group type: EXPERIMENTAL
Intervention: Controlled-Intermittent Anal Dilatation (CIAD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lateral Internal Sphincterotomy (LIS)
Number of subjects: 40
Study: 16126804

Group type: EXPERIMENTAL
Intervention: Intramuscular gentamicin 5 mg/kg/day once-daily (OD)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Intramuscular gentamicin 5 mg/kg/day thrice-daily (TD)
Number of subjects: 310
Study: 15071015

Group type: EXPERIMENTAL
Intervention: Structured treatment interruptions (STIs)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No structured treatment interruptions (Control)
Number of subjects: 51
Study: 11053508

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Combined vitamin A and iron supplementation
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 9564977

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 336 microg/day by metered dose inhaler (MDI)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) 800 microg/day by MDI with a built-in tube extender
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study: 8044782

Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT‐11) administered at dose levels ranging from 50 to 145 mg/m2 (30‐90 min i.v. infusion)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT‐11)
Number of subjects: 59
Study: 3051962

Group type: EXPERIMENTAL
Intervention: Golytely-RSS plus oral bisacodyl
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard 1-day diet/cathartic method
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Golytely-RSS
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard preparation
Number of subjects: 100
Study: 29561461

Group type: EXPERIMENTAL
Intervention: Pharmacist-led educational intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 80
Study: 27816302

Group type: EXPERIMENTAL
Intervention: Central airways obstruction (CAO) defined by FEV1/FVC <0.7
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Small airways obstruction (SAO) defined by FEV1/FVC ≥0.7 plus MEF <60% of predicted value
Number of subjects: 585

Group type: COMPARATOR
Intervention: No airways obstruction
Number of subjects: 585
Study: 24788581

Group type: EXPERIMENTAL
Intervention: Multidimensional Stimulation group Therapy (MST)
Number of subjects: 60
Study: 23378471

Group type: EXPERIMENTAL
Intervention: 1.36% glucose during the day and 1 overnight exchange of 1.36% glucose
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 1.36% glucose during the day and 1 overnight exchange of 2.27% glucose
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 1.36% glucose during the day and 1 overnight exchange of 3.86% glucose
Number of subjects: 83
Study: 21397096

Group type: EXPERIMENTAL
Intervention: PCB plus 10% lidocaine spray
Number of subjects: 77

Group type: COMPARATOR
Intervention: Paracervical blocks (PCB)
Number of subjects: 77
Study: 18310675

Group type: EXPERIMENTAL
Intervention: Ketamine gargle (40 mg in saline 30 ml)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (saline 30 ml)
Number of subjects: 46
Study: 17062365

Group type: EXPERIMENTAL
Intervention: FGF 1 L/min with 1% isoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FGF 2 L/min with 1% isoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FGF 3 L/min with 1% isoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FGF 1 L/min with 2% isoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FGF 2 L/min with 2% isoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FGF 3 L/min with 2% isoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 60
Study: 12150370

Group type: EXPERIMENTAL
Intervention: Oral breathing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nasal breathing
Number of subjects: 20
Study: 10433004

Group type: COMPARATOR
Intervention: Fasting conditions
Number of subjects: 26

Group type: COMPARATOR
Intervention: Postprandial conditions
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 26
Study: 7748687

Group type: EXPERIMENTAL
Intervention: Neonatal Early Discharge and Family Support Programme (NEDP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NEDP
Number of subjects: 0
Study: 2124470

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg once a day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 373792

Group type: EXPERIMENTAL
Intervention: Loestrin-20 (20 microgram ethinyl oestradiol and 1 mg norethisterone acetate)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Microgynon-30 (30 microgram ethinyl oestradiol and 150 microgram levonorgestrel)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Loestrin-20
Number of subjects: 55

Group type: COMPARATOR
Intervention: Microgynon-30
Number of subjects: 55
Study: 6365466

Group type: EXPERIMENTAL
Intervention: Piretanide 3 mg per day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Piretanide 6 mg per day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Piretanide 12 mg per day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 31022160

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (IL‐I) with increased physical activity and reduced caloric intake, more frequent external support than control group.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (IL‐I)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (less frequent external support)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29158143

Group type: EXPERIMENTAL
Intervention: 600 mg Tobrate™
Number of subjects: 9
Study: 28128758

Group type: EXPERIMENTAL
Intervention: Low-osmolar iodinated contrast media (770 mOsm/kg H2O - Group 1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Iso-osmolar iodinated contrast media (290 mOsm/kg H2O - Group 2)
Number of subjects: 16
Study: 24419562

Group type: EXPERIMENTAL
Intervention: Green tea (700 ml/day for 14 days)
Number of subjects: 10
Study: 22748970

Group type: EXPERIMENTAL
Intervention: Rabeprazole granules mixed with soft food or infant formula (10 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Rabeprazole suspension with inactive vehicle granules (reference)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: All treatment-emergent adverse events (TEAEs)
Number of subjects: 35
Study: 21131038

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 239

Group type: COMPARATOR
Intervention: Idarubicin
Number of subjects: 239
Study: 17494097

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (T) gel (100 mg/d) plus depomedroxyprogesterone acetate (300 mg intramuscularly every 12 weeks) with GnRH antagonist acyline (300 microg/kg subcutaneously every 2 weeks for 12 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Transdermal testosterone (T) gel (100 mg/d) plus depomedroxyprogesterone acetate (300 mg intramuscularly every 12 weeks) without GnRH antagonist acyline
Number of subjects: 20
Study: 15737074

Group type: EXPERIMENTAL
Intervention: Iterative partial least squares based on the Buckley-James estimating equation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other dimension reduction techniques
Number of subjects: 0
Study: 11972294

Group type: EXPERIMENTAL
Intervention: Plasma Volume Expansion (PVX) using Dextran [6 %] or Pentaspan [10 %] (6.7 ml/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Plasma Volume Expansion (PVX)
Number of subjects: 8
Study: 9918907

Group type: EXPERIMENTAL
Intervention: Losartan 25 mg orally once daily for 1 week
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (no losartan)
Number of subjects: 70
Study: 8525398

Group type: COMPARATOR
Intervention: IVER 100
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: IVER 400
Number of subjects: 43
Study: 2178724

Group type: EXPERIMENTAL
Intervention: Uro-Vaxom (UV)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 232563

Group type: EXPERIMENTAL
Intervention: Methadone (7.5, 15, 30 mg/70 kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Morphine (10 or 20 mg/70 kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Heroin (3, 6, 12 mg/70 kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31944801

Group type: EXPERIMENTAL
Intervention: More Appreciation (MA) intervention
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Less Criticism (LC) intervention
Number of subjects: 803

Group type: COMPARATOR
Intervention: Fruit and Vegetable (FV) control arm
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: All arms (MA, LC, FV)
Number of subjects: 803
Study: 30885157

Group type: EXPERIMENTAL
Intervention: Co-administration of ivermectin and albendazole
Number of subjects: 600

Group type: COMPARATOR
Intervention: Albendazole monotherapy (control)
Number of subjects: 600
Study: 29631920

Group type: EXPERIMENTAL
Intervention: Telephone-guided self-help intervention for common mental health difficulties
Number of subjects: 27
Study: 26763343

Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no pessary)
Number of subjects: 0
Study: 25045908

Group type: EXPERIMENTAL
Intervention: Continuation-phase cognitive therapy (C-CT)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: All groups (C-CT, FLX, and placebo)
Number of subjects: 241
Study: 22640673

Group type: EXPERIMENTAL
Intervention: Nonconventional elastomeric ligatures
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional elastomeric ligatures
Number of subjects: 20
Study: 20306476

Group type: EXPERIMENTAL
Intervention: Oral calcitriol 0.25 mcg twice daily for 1 week, followed by oral calcitriol 0.50 mcg twice daily for 1 week
Number of subjects: 9

Group type: COMPARATOR
Intervention: Healthy age-matched controls
Number of subjects: 9
Study: 17416125

Group type: EXPERIMENTAL
Intervention: Cross-body stretch
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sleeper stretch
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 54
Study: 16387087

Group type: COMPARATOR
Intervention: Thymoglobulin
Number of subjects: 196

Group type: COMPARATOR
Intervention: Campath 1H
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Steroid-free low-dose tacrolimus immunosuppressive monotherapy
Number of subjects: 196
Study: 12553382

Group type: EXPERIMENTAL
Intervention: Automatic tube compensation (30 minutes)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pressure support (7 cmH2O, 30 minutes)
Number of subjects: 12

Group type: COMPARATOR
Intervention: T-piece breathing (30 minutes)
Number of subjects: 12
Study: 10084467

Group type: EXPERIMENTAL
Intervention: salmeterol + beclomethasone dipropionate (BDP, 500 microg bid)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo + BDP
Number of subjects: 12
Study: 7484878

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) plus graduated compression stockings (GCS)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Graduated compression stockings (GCS) alone
Number of subjects: 344
Study: 2099194

Group type: EXPERIMENTAL
Intervention: Genivir (DIP-253) 1% cream
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 100
Study: 6117063

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atenolol (200 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Acebutolol (400 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oxprenolol (160 mg/day)
Number of subjects: 24
Study: 30820738

Group type: EXPERIMENTAL
Intervention: ocrelizumab 600 mg administered by intravenous infusion every 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: interferon (IFN) β‐1a 44 µg subcutaneous three times per week
Number of subjects: 0
Study: 29976291

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 57
Study: 27814749

Group type: EXPERIMENTAL
Intervention: Single-implant mandibular overdenture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional complete denture
Number of subjects: 0
Study: 24443820

Group type: EXPERIMENTAL
Intervention: Tailored weekly e-mail reminder (n = 175)
Number of subjects: 1337

Group type: EXPERIMENTAL
Intervention: Standardized weekly e-mail reminder (n = 176)
Number of subjects: 1337

Group type: EXPERIMENTAL
Intervention: No e-mail reminder (n = 175)
Number of subjects: 1337

Group type: COMPARATOR
Intervention: Waitlist control group (n = 180)
Number of subjects: 1337
Study: 22042371

Group type: COMPARATOR
Intervention: Conjugated equine estrogen (CEE) alone
Number of subjects: 27347

Group type: COMPARATOR
Intervention: Conjugated equine estrogen (CEE) plus medroxyprogesterone (MPA)
Number of subjects: 27347
Study: 19395973

Group type: EXPERIMENTAL
Intervention: Tramadol alone (1.5 mg kg(‐1))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of tramadol (1 mg kg(‐1)) and paracetamol 1 g
Number of subjects: 60